Jaarbeurs Utrecht, Netherlands
Booth: 201
Connect with Ncardia at the Safety Pharmacology Society (SPS) Annual Meeting to meet the solution that’s reshaping predictive toxicology and preclinical safety testing: iPSC-based platforms. Our high-throughput, human-relevant models are built to meet the rigorous demands of cardiac, neurological, and stem cell research — offering the precision and scalability required for modern safety pharmacology.
Let’s meet at SPS 2025 to discuss how our discovery services and iPSC-derived models can support your next study from early screening to regulatory submission.
Presentation:
“Development and Characterization of Non-Human Primate iPSC-Derived Ventricular Cardiomyocytes for High-Throughput Safety Pharmacology Screening ”
Speaker: Ilse Veldkamp-Baak MS, Scientist
Date: October 13th, 3-5 p.m.
Poster: #062
October 14th, 2-3 p.m.
October 15th, 11:10 a.m – 12:10 p.m.
Presentation:
“A Human iPSC-Based Platform for Functional Toxicity Screening of CNS-Targeted RNA Therapeutics”
Speaker: Shushant Jain, PhD, Director of Discovery Technology
Date: October 14th, 3-5 p.m.
Poster Only: “A Physiologically Relevant 3D iPSC-Based Cardiac Microtissue Model for High-Throughput Screening"
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.